General meetings

The shareholders’ right to decide on the company’s affairs is exercised at its highest decision-making body – the general meeting (the annual general meeting or an extraordinary general meeting). The general meeting decides, for example, on changes to the articles of association, the election of the Board of Directors and auditors, adoption of the income statement and balance sheet, discharge from liability of the Board of Directors and the CEO, the appropriation of profit or loss, the principles for the appointment of the nomination committee and remuneration guidelines for the Management Team.

General meetings shall be held in Lund, Sweden. Notice convening the annual general meetings and extraordinary general meetings where amendments to the articles of association are to be addressed, shall be issued no earlier than six weeks and no later than four weeks prior to the meeting. Notice convening other extraordinary general meetings shall be issued no earlier than six weeks and no later than three weeks prior to the meeting. A shareholder who wishes to have a matter considered by the Annual General Meeting on may submit a written request to the Board. Proposals for the agenda shall be submitted no later than seven weeks before the Annual General Meeting.

Immunovia Extraordinary General Meeting, November 21, 2023

Extraordinary General Meeting 21 November, 2023 (PDF)

Proxy form (PDF)

Form of stock option notice agreement and option plan (PDF)

Terms and conditions for warrants 2023:2034:1 (PDF)

Terms and conditions for warrants 2023:2034:2 (PDF)

Board of directors proposal (PDF in Swedish)

The Board of Directors report (PDF)

The auditor’s statement (PDF in swedish)

The Nomination Committee’s Statement (PDF)

Appendix to Immunovia AB (PUBL) long term incentive plan for United States Residents (PDF)

Protocol from Extraordinary General Meeting 21 November 2023 (PDF in Swedish)

Archive